<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386851</url>
  </required_header>
  <id_info>
    <org_study_id>031-402-00089</org_study_id>
    <nct_id>NCT03386851</nct_id>
  </id_info>
  <brief_title>Abilify Maintena PMS in Schizophrenia Patients</brief_title>
  <official_title>Post-Marketing Surveillance of Safety and Effectiveness of Abilify Maintena® Injections in Korean Patients With Schizophrenia Under the &quot;New Drug Re-Examination&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post-Marketing Surveillance (PMS) of Abilify Maintena® Injections in accordance
      with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards:
      Ministry of Food and Drug Safety(MFDS) Notification).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence rate and the number of Adverse Events (AE)/ Adverse Drug Reactions (ADR), Serious AE/ADR, Unexpected AE/ADR</measure>
    <time_frame>until 28 days after discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to last visit in Clinical Global Impression - Severity of Illness scale (CGI-S) score.</measure>
    <time_frame>at least 12, 24 weeks interval from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Improvement scale (CGI-I) score at the last visit</measure>
    <time_frame>at least 12, 24 weeks interval from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to last visit inPersonal and Social Performance Scale (PSP) score.</measure>
    <time_frame>at least 12, 24 weeks interval from baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Schizophrenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Schizophrenia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with schizophrenia

          -  Patients who are prescribed Abilify Maintena® Injections treatment as per
             investigator's medical judgment

          -  Patients giving written authorization to use their personal and health data and
             starting Abilify Maintena® Injections treatment after agreement is in place and
             investigators provide the explanation about objective and feature of the surveillance

        Exclusion Criteria:

          -  Patients with known hypersensitivity to Aripiprazole or any excipients of Abilify
             Maintena® Injections

          -  Elderly patients with dementia related psychosis

          -  Patients who have been treated with Abilify Maintena® Injections

          -  Patients with score 0(Not assessed) or 1(Normal, not at all ill) in the Clinical
             Global Impression-Severity(CGI-S)

          -  Patients participating in other clinical trial

          -  All patients who in medical judgment of the investigator would not be appropriate for
             inclusion criteria in the surveillance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui-Yeong Shim</last_name>
    <email>hyshim@otsuka.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>St.John of God Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>psychiatrist</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

